02:48 , Dec 19, 2015 |  BC Extra  |  Company News

BMS divests HIV pipeline to ViiV

Bristol-Myers Squibb Co. (NYSE:BMY) said it will divest its discovery-stage, preclinical and clinical HIV assets to ViiV Healthcare, an HIV-focused JV majority-owned by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The companies struck separate deals for late and...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

BMS-955176: Additional Phase IIa data

Data from 60 patients with HIV-1 subtype B in the open-label Part A portion of the international Phase IIa AI468002 trial showed that once-daily oral BMS-955176 reduced median HIV-1 RNA levels from baseline to day...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

BMS-955176: Additional Phase IIa data

Data from 28 patients with HIV-1 subtype B in the open-label Part B portion of the international Phase IIa AI468002 trial showed that once-daily 40 mg oral BMS-955176 plus 400 mg Reyataz atazanavir reduced median...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

Bristol-Myers infectious news

Bristol-Myers said it will discontinue drug discovery in virology and cut about 100 jobs as part of an ongoing R&D reorganization announced in 2013. The company said the change will not affect its clinical-stage and...
01:23 , Jun 26, 2015 |  BC Extra  |  Company News

BMS ending virology discovery, building Cambridge hub

Bristol-Myers Squibb Co. (NYSE:BMY) said it will discontinue drug discovery in virology as part of an ongoing R&D reorganization. The company said the change will not affect its clinical-stage and marketed virology products. BMS will...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

BMS-955176: Phase IIa data

The double-blind, dose-escalation, international Phase IIa AI468002 trial in 60 patients with HIV-1 infection showed that once-daily oral BMS-955176 for 10 days met the primary endpoint of reducing plasma HIV-1 RNA levels from baseline to...
08:00 , Jan 5, 2015 |  BioCentury  |  Strategy

Guest Commentary: The Tipping Point

Roger Longman, CEO, Real Endpoints LLC and Jane Borne, Senior Research Pharmacist, Real Endpoints LLC   That boom you heard on Dec. 22 followed by the thud of Gilead Sciences Inc. 's stock price was...